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INTRODUCTION 
 
Edema of the retina is an extremely common condition occurring to some degree in 
most circulatory disturbances and all inflammatory conditions. Broadly defined 
macular edema is an abnormal thickening of the macula with accumulation of 
excess fluid in the extracellular space of the neurosensory retina. 
The term cystoids macular edema applies when there is accumulation of fluid in 
cyst like spaces within the macula as evidenced by clinical examination, 
flourescien angiography or OCT. 
Macular edema in its various forms can be considered the leading cause of central 
vision loss in the world and is therefore of enormous medical and socio-economic 
importance. 
 
 
 
 
 
 
 
 ANATOMY OF THE MACULA 
 
Macula is the optical, functional and organic focal point of the eye. It is concerned 
with precise visual functions of acuity, form sense, color differentiation and 
stereopsis. 
 
According to Wolff, the macula is an oval zone of yellow coloration within the 
central retina approximately 5 mm in diameter. The yellow color of the macula is 
probably from the presence of the carotenoid pigment Xanthophyll in the ganglion 
calls and the bipolar cells in this area. 
The side walls of the macula is the clivus which slopes gently towards the fovea 
centralis. Fovea is the center of the area centralis and is located 4 mm temporal to 
the center of the optic disc and 0.8 mm below the horizontal meridian. Its thickness 
is 0.25 mm, diameter is 1.85 mm and it corresponds to 5 degrees of visual field. 
Foveola is at the center of the fovea where the retinal layers are thinner. It is of 
0.13 mm thickness, 0.35 mm in diameter and corresponds to 1 degree of visual 
field. It is the area of highest visual acuity because of the sole presence of cone 
photoreceptors and its avascularity. It appears deeper red than the adjacent retina 
because of the rich choroidal circulation and abundant choriocapillaris. Parafovea 
is a 0.5 mm wide zone around the fovea. Perifovea is a 1.5 mm band beyond the 
parafovea. 
HISTOPATHOLOGY 
The retina as such has 10 layers which are as follows- 
1. Retinal pigment epithelium 
2. Photoreceptor layer of rods and cones 
3. External limiting membrane 
4. Outer nuclear layer 
5. Outer plexiform layer 
6. Inner nuclear layer 
7. Inner plexiform layer 
8. Ganglion cell layer 
9. Nerve fiber layer. 
10. Internal limiting membrane 
At the fovea, the only layers present are the 
1. Retinal pigment epithelium 
2. Photoreceptors ( only cones) 
3. External limiting membrane  
4. Outer nuclear layer 
5. Inner fibers of photoreceptors ( Henle’s layer) 
6. Internal limiting membrane 
Thus the fovea has no inner nuclear layer, inner plexiform layer or ganglion cell 
layer and practically no nerve fiber layer. 
At the macula the ganglion cells are much more numerous than elsewhere in the 
retina, being arranged in several layers. The OPL is made up of arborisation of 
axons of rods and cones with bipolar cell dendrites. it also includes Muller’s fibers 
and the horizontal cell processes. This layer has a reticular structure but as the 
macula is approached it takes a fibrous structure called the ‘Henle’s fiber layer’. 
The fibers run at first vertically, then obliquely near the macula and finally parallel 
to the surface. This layer is thickest at the macula but almost absent at the fovea. 
There is also a progressive disappearance of rods.i The RPE and choriocapillaris 
are thicker than at the macula. This is important since the macula has no retinal 
blood vessels. At the fovea the layers of the retina are spread aside so that light 
may fall directly on the cones. Each cone is connected to only one ganglion cell ( 
in other area each ganglion cells connects up to 100 rods). At the center of the 
fovea cone cells are located in a 50µ diameter area and are separated from each 
other by relatively wide spaces of watery cytoplasm belonging to Muller’s fibres. 
The thinness of the basal lamina and the watery cytoplasm allow light to pass 
throughii. 
ANATOMIC PECULARITIES OF THE MACULA CAUSING AN 
EXAGGERATED RESPONSE TO PATHOLOGICAL 
PROCESSES. 
The peculiar susceptibility of the macula to a number of different pathological 
processes both local and generalized is called the ‘exaggerated response of the 
macula’iii. The causes for this are listed below- 
1. VASCULAR SUPPLY: 
The arcade arrangement of the capillaries which arise as terminal parts of 
an end artery system, together with the central avascular zone make the fovea a 
‘watershed’. Local impairment of metabolism , whether from disturbances in 
perfusion and accumulation of metabolites or from the effects of capillary 
damage, lead to extra cellular fluid accumulation at a quicker rate than what can 
be absorbed.  
2. TISSUE ARCHITECTURE: 
The processes of Muller’s cells run horizontally in the OPL, hence the 
retina loses its compact nature and this laxity enables large quantities of extra 
cellular fluid or exudates to be accommodated in the macular region leading to 
the characteristic cystiod macular edema. 
3. CELLULAR CONSTITUENTS: 
The ganglion cells have a high metabolic rate and their dysfunction due 
to any cause leads to rapid accumulation of tissue metabolites here. Most 
metabolites have a vasodilator effect and this along with the underlying hypoxia 
can lead to CME 
4. INTERNAL LIMITING MEMBRANE: 
The vitreous is an excellent diffusing medium and the ILM provides little 
additional interference to the progress of toxic substances arising from the iris, 
peripheral choroid and pars plana. These substances may traverse the vitreous 
and because of the thinness and adherence of the ILM in the foveal region, may 
preferentially disturb the function of the cells which are highly concentrated 
around the foveal rim, and also affect the macular capillary permeability. 
5. CHOROID AND RPE: 
The macular choroid and the RPE are also the preferential sites for 
degenerative changes which may be hereditary, toxic or arteriosclerotic. There 
is a predisposition for choroidal vascular diseases with decompensation and 
hemorrhage in the central area which is thought to be because RPE in the fovea 
is very active metabolically and this hyperactivity along with the special 
homodynamic effects of the narrow choroidal capillaries may lead to increased 
susceptibity. 
MACULAR EDEMA 
The extra cellular space  of the retina normally constitutes a small proportion of its 
total volume. Active transport of electrolytes and larger molecules from the retina 
across the retinal pigment epithelium to the blood maintains this situation. 
Disruption of either the outer or the inner blood retinal barrier leads to leakage of 
plasma proteins and fluid into the extra cellular space. This is often accompanied 
by accumulation of fluid in the macular are usually in the area of  outer plexiform 
layer and inner nuclear layer. Retinal edema localized to the macula is called 
macular edema. More generalized leakage leads to diffuse thickening of the 
posterior pole. Accumulation of fluid in cystic spaces leads to cystoids macular 
edema. 
 
 
CYSTOID MACULAR EDEMA 
Causes for cystoids degeneration of the macula have been classified by 
Duke – Elder asiv 
• Senile degeneration 
• Vascular disorders- arteriosclerosis, CRVO,CRAO,BRVO, retinal periphlebitis, 
hypertensive retinopathy, diabetic retinopathy. 
• Inflammatory disorders- chorioretinitis, iridocyclitis 
• Degenerative conditions affecting the macula- RD, macular dystrophies, 
retinitis pigmentosa. 
• Trauma 
• Glaucoma 
• Hereditary macular cystoid dystrophy 
 
Other conditions mentioned by Stephen J Ryan arev- 
• Choroidal melanoma, choroidal hemangioma 
• Retinal detachment 
• Epinephrine maculopathy 
• Nicotinic acid maculopathy 
• After intraocular surgeries- cataract extraction, vitrectomy, PKP,glaucoma 
filtering procedures. 
• Tractional maculopathies- vitromacular traction syndrome, epiretinal 
membrane, myopic traction maculopathy. 
• Optic nerve head abnormalities- optic disc pit, coloboma, diabetic pappilopathy, 
neuroretinitis. 
 
 
  
 
 
DIABETIC CYSTOID MACULAR EDEMA 
 
It is the most frequent cause of moderate visual impairment in patients with 
NPDR.This is best detected by Slit lamp with +60D, +78D, +90D or Macular 
contact lens. Its incidence increases with type of DM (its occurrence is more 
common in type 2 DM) , duration of DM, age of onset, use of insulin, uncontrolled 
DM, associated risk factors like Hypertension, Hyper lipedemia, anemia, 
nephropathy. 
Hyper glycemia is the main inciting factor which causes Blood Retinal 
Barrier breakdown by 3 mechanisms: 
1. Increased paracellular transport due to disruption of cell junction 
2. Loss of endothelial cell integrity 
3. Increased transcellular transport through damaged endothelium 
CLINICAL FEATURES: 
Diabetic Macular Edema has following features: 
1. Thickening of macula 
2. Blurring of underlying choroidal vascular pattern. 
3. Loss of foveolar light reflex if foveola is involved.  
4. Cystoid spaces 
5. Lipid exudation from leaking Microaneurysms forming circinate retinopathy 
 
CLASSIFICATION: 
Focal Edema :  
Areas of focal leakage from micro aneurysms and dilated capillary 
segments. These focal areas of thickening are delineated from adjacent healthy 
retina by complete or partial ring of Hard Exudates. 
Diffuse Edema 
Breakdown of Blood Retinal Barrier with leakage from Micro aneurysms 
and dilated capillary bed throughout posterior retina causes diffuse edema. It 
differs from focal edema by: 
1. Diffuse edema usually not associated with Hard exudates. Even when edema 
resolves spontaneously it does not leave hard exudates. 
2. Cystoid spaces develop more commonly in DME. It is visible clinically, but 
seen better in late phase of FFA & on OCT as hyper reflective spaces with 
hyper reflective septa. 
3. Mostly bilaterally symmetrical. 
4. May disappear spontaneously at same time in both eyes even without laser only 
to reappear spontaneously.   
5. Certain systemic features may be associated with exacerbation & amelioration 
of DME & include CVS, renal, Hypertension, Pre eclampsia  
  Ischemic edema 
Ischemic type of lesion has the following features : 
• Enlargement of Foveal Avascular Zone(FAZ) 
• Irregularities of FAZ 
• Capillary budding into FAZ 
• Widening of intercapillary space and capillary dropout in perifoveal area 
 
CSME (Clinically Significant Macular Edema) 
1. Thickening of the retina < 500 microns from the center of the macula. 
2. Hard exudates with thickening of the adjacent retina located 500 microns from 
the center of macula 
3. A zone of retinal thickening, 1 disc area or larger in size located 1 disc diameter 
from center of macula. 
FFA: 
 Focal macular edema shows areas of leakage mainly micro aneurysms that 
show leakage in late phase. Diffuse macular edema shows dilated capillary 
network & areas of Capillary Non Perfusion areas with extravasations of dye in 
late phase. Dye may pool in cystoids spaces if present 
International Clinical DME Severity Scale:  
1. DME absent: No thickening or hard exudates in posterior pole. 
2. DME present : 
Some retinal thickening or hard exudates in posterior pole. It can be mild, 
moderate or severe. 
CYSTOID MACULAR EDEMA IN POST INTRAOCULAR 
SURGERIES 
Theories explaining aphakic and pseudo phakic CME 
 
 
Vitreous traction theory- 
Constant constriction and dilatation of the pupil created pulling on the 
anterior vitreous strands which is transmitted to the vitreous base and to the macula 
by presumed connections between the posterior hyaloid and the surface of the 
macula  
Inflammation theory- 
CME following cataract extraction  ( Irvine –Gass) syndrome can be seen in 
approximately 20% of uncomplicated casesvi. Prostaglandins most likely 
synthesized by the anterior uveal tissues, have been implicated in causing macular 
capillary hyperpermeability in these cases. Since the eye does not contain the 
enzyme 15-PG dehydrogenase to deactivate prostaglandins, their removal is 
dependent on an active transport pump called Bito’s pump present in the ciliary 
epithelium. This pump is inoperable for at least 3 weeks after ocular trauma. 
CME remains the most common cause of vision loss after cataract surgery. 
A higher incidence is seen when surgery is complicated by vitreous loss, vitreous 
adhesions to the cataract wound or other anterior segment structures, iris damage 
or retained lens material. 
The risk of developing CME is substantially higher in patients with pre 
existing conditions known to produce vasoactive stimuli such as diabetic 
retinopathy and uveitis. 
CYSTOID MACULAR EDEMA IN RETINAL VENOUS 
OCCLUSIONS. 
         An immediate consequence of retinal venous thrombosis is elevation                     
of the intravascular pressure in the retinal veins distal to the occlusion site.   Due to 
this there is an increased transmural hydrostatic pressure in the retinal capillaries 
.This leads to greater transudation of fluid into the extra cellular space. 
Breakdown of the blood retinal barrier, mediated by cytokines such as 
VEGF that are upregulated in the hypoxic retina, greatly facilitates the 
extravasation of fluids as well as large protein molecules.vii 
In this manner both central and branch retinal vein occlusions commonly result in 
macular edema which tends to be chronic, difficult to treat and visually disabling. 
In many eyes vision loss is exacerbated by macular hemorrhage, macular ischemia, 
submacular fluid with secondary RPE changes or traction from ERM or 
vitreomacular adhesions. 
 
CLINICAL EVALUATION OF CYSTOID MACULAR EDEMA- 
1. Visual Acuity 
Loss of vision mainly depends on the involvement of the macula. 
2. Color Perimetry 
Field charting by perimetry bay reveal scotomas corresponding to areas of 
involvement in the fundus 
3. Color Vision  
The most common defect observed is blue yellow. In diabetes the sensitivity 
of blue cones are depressed. These defects are best detected by Farnsworth 
Munsell 100 hue test. 
4. Stereoscopic indirect ophthalmoscope 
This technique is of special importance because it allows the examiner to 
integrate the view of the entire retina. This allows the examiner to form a clearer 
understanding of the cause &forces involved in the various pathological features 
involving the retina. 
5. Slit lamp Biomicroscope 
Since the bio microscope is focused about 95mm, the retina is not visible 
unless any of the below optical methods are used: 
1. Goldmann contact lens- 3 mirror 
2. Hruby lens 
3. 90 D, 78 D condensing lens. 
By combining these maneuvers, it is possible to see virtually the entire 
retina. 
6. Direct Ophthalmoscope 
Though the area of field observed is smaller, increased magnification 
obtained with this method allows detailed examination of the various details of the 
fundus. 
7. Threshold Amsler Grid Testing 
 This rapid, sensitive and high yield means of assessing the central fields in 
patients with diabetic retinopathy. 
8. Photo Stress Test 
        After images and central scotomas persist after a long time. This explained the 
prolonged re-adaptation times in photo stress test in the affected eye. 
9. Electrophysiology 
• Electro Retinography: 
Early stages of diabetic retinopathy may reveal abnormalities of oscillatory 
potential in the ascending limit of the b wave. Delay in implicit time occurs as the 
macular edema progresses 
• Electro Oculography: 
This test may reveal abnormal light to dark ratio(Arden’s ratio)  
• Visually Evoked Responses: 
The macular disease with edema, the VER shows amplitude reduction 
depending on the reduced visual acuity with no change in latency. 
 
10. Fluorescein Angiography 
This is one of the mandatory investigations needed in macular edema for: 
1. Confirmation of the diagnosis 
2. Documentation of the various lesion 
3. Deciding about the management 
4. Follow up 
11. OCT :  
This investigative modality can also be used for diagnosis and follow-up. It 
has the added advantage of being non invasive. In addition parameters like the 
macular thickness can be quantified on subsequent visits. The macular edema 
patterns seen on OCT are as follows-  
1. Sponge like retina :  
It is mostly confined to outer retinal layers due to backscattering from 
intraretinal fluid.   
       
2. Cystoid macular edema :   
Cystoid spaces confined to outer retina mostly. In long standing cases they 
fuse to form large cyst. 
3. Serous retinal detachment : 
Hypo reflective space under fovea. It may disappear following laser. 
4. Tractional macular edema : 
Foveo vitreal traction causes detachment of fovea. Its an indication for Pars 
Plana Vitrectomy to release traction. Laser will worsen macular edema in these 
cases. 
5. Taut Posterior Hyaloid Membrane: 
Cystoid spaces confined to outer retina mostly. In long standing cases they 
fuse to form large cyst. 
EVOLVING THERAPIES FOR MACULAR EDEMA 
Laser photocoagulation: 
ME secondary to retinovascular disease, especially that caused by diabetic 
retinopathy and BRVO, responds well to focal or grid laser photocoagulation. 
Focal laser treatment is used to close micro aneurysms, while grid laser treatment 
reduces leakage from damaged, permeable, macular capillaries. The highest 
success rates with laser treatment are achieved when the leakage is localized. 
The Early Treatment for Diabetic Retinopathy Study (ETDRS) established 
the indications and guidelines for laser treatment in diabetic ME.viii Laser treatment 
is indicated for clinically-significant ME (CSME), which is defined by at least one 
of the following: 
• Retinal thickening involving or within 500μm of the foveal avascular zone 
• Hard exudates at or within 500μm of the foveal avascular zone, if associated 
with thickening of the adjacent retina 
• Retinal thickening >1 disc area within 1 disc diameter of the center of the 
foveal avascular zone.  
Moderate visual loss was reduced by 50% in patients who received laser 
therapy in the ETDRS. Grid photocoagulation has also proven to be of benefit for 
BRVO, but not for central retinal vein occlusion (CRVO). In the Branch Vein 
Occlusion Study, 65% of grid laser-treated eyes gained at least 2 lines of vision, 
compared with 37% of untreated eyesix. Laser treatment also reduced the risk of 
vision loss. In the Central Vein Occlusion Study (CVOS), grid laser did not have a 
statistically significant effect on vision, although there was a trend towards better 
vision in patients aged <60 years who underwent laser treatment. 
 
Topical therapy: 
Several studies have documented the utility of topical nonsteroidal anti-
inflammatory drugs (NSAIDs) for the prevention and treatment of ME after 
cataract surgery.x A double-masked, randomized, placebo-controlled trial to 
evaluate the effect of Ketorolac 0.5% ophthalmic solution on chronic aphakic and 
pseudophakic CME determined that this drug was beneficial for the primary 
outcome measure (ie, Snellen acuity)xi. The efficacy of topical Flurbiprofen 0.03% 
and Indomethacin 1% in preventing pseudophakic ME was examined in a 
randomized, double-masked study that revealed a reduced incidence of clinical and 
angiographic CME in the early postoperative period. Recently, two new topical 
NSAIDs – Bromfenac 0.09% and Nepafenac 0.1% – have been Food and Drug 
Administration (FDA)-approved for post-cataract surgery inflammation and pain. 
There have been reports, particularly for Nepafenac, of their potential for 
preventing pseudophakic ME.xii Nepafenac is a pro-drug that is converted after 
corneal penetration to Amfenac, a potent NSAID. In one animal model, Nepafenac 
was shown to inhibit prostaglandin in the vitreous humor to a much greater extent 
than other traditional NSAIDs. Whether this efficacy will translate into improved 
prevention or treatment of pseudophakic CME is currently under investigation. 
Corticosteroid drops, alone or in combination with NSAID drops, have been 
studied for the treatment of pseudophakic CME. Treatment with topical NSAIDs 
appears to be more effective than topical steroids alone. However, combination 
therapy with topical NSAID and prednisolone acetate was superior to either one 
alone in treating CME. Consensus for topical NSAID use has not been formally 
established; however, the standard of care for many cataract surgeons is to use both 
NSAIDs and topical steroids for at least 1 to 2 days preoperatively and for several 
weeks postoperatively. In higher risk patients, such as those with pre-existing 
ocular inflammation or diabetes, extended preoperative and postoperative use is 
typically employed. Patients must be monitored for the side effects of both 
NSAIDs (corneal toxicity) and corticosteroid use (increased intraocular pressure). 
Systemic therapy: 
Systemic NSAIDs have been examined as a treatment of uveitic ME. A 
recent study of oral naproxen or rofecoxib revealed that these medications had no 
effect on CME. However, these patients also had active, intraocular inflammation. 
NSAIDs may have some role in the prevention of a recurrence of CME after 
inflammation is controlled, although this scenario is still under investigation.xiii The 
potential for NSAIDs to cause gastrointestinal ulceration or liver toxicity must be 
addressed with patients before initiating this class of therapy. Carbonic anhydrase 
inhibitors (CAIs) reduce ME that can occur in association with retinitis pigmentosa 
(RP). A randomized crossover study demonstrated improvement in visual acuity in 
>80% of all RP patients who received acetazolamide.xiv The usual starting dose in 
these patients is 500 mg/day. Sometimes, CAIs are used to treat uveitis-associated 
ME, although the potential benefits have not been substantiated by clinical 
research. In fact, there is conflicting evidence for CAI use in this situation, with 
one study demonstrating a statistically significant improvement in visual acuity in 
the treated group, while another failed to show an improvement despite a reduction 
in the amount of edema evident on FA.xv The evidence for the usefulness of CAIs 
in the treatment of pseudophakic ME is even less robust. Systemic corticosteroids 
have a long history of successful use in the treatment of uveitis-associated ME. In 
severe cases, intravenous steroids are recommended during induction therapy. 
More typically, treatment is initiated with a high oral dose, approximately 1 mg/kg, 
followed by a standard slow taper over several weeks to months. Tapering the 
medication dose too rapidly is associated with a higher chance of recurrence. The 
short-term side effects of steroids, including mood alterations, difficulty sleeping, 
increased appetite, and the potential for sudden worsening of a diabetic state, must 
be discussed with the patient. There are a few reports on the successful use of 
systemic steroids in the treatment of recalcitrant cases of pseudophakic CME, but 
this indication has not been well established. Steroid-sparing immunomodulators 
have been shown to be effective in the treatment of uveitis, but their utility in ME 
is less clear. 
 
Periocular and intravitreal corticosteroids:  
The rationale for the use of corticosteroids in the treatment of ME stems from the 
observation that steroids influence by multiple pathways that contribute to 
breakdown of the blood-retinal barrier and edema. Corticosteroids inhibit VEGF 
and other cytokines and growth factors that regulate endothelial tight cell 
junctions. They also reduce the synthesis of prostaglandins and leukotriene, two 
local potent inflammatory mediators. Periocular steroids may be given with 
equivalent benefit either as an injection into sub-Tenon’s space or a peribulbar 
(usually inferior) location. Either type of depot administration achieves a more 
sustained treatment effect than topical corticosteroid drops alone. At the least, 
peribulbar steroids provide a short-term benefit in some cases of ME associated 
with diabetes mellitus, BRVO, CRVO, or pseudophakia. Periocular steroids are 
particularly useful in cases of anterior uveitis that are not responsive to topical 
therapy. In such cases, periocular steroids can both quell the inflammation and 
diminish the retinal thickening produced by the ME. 
 
Role of intravitreal steroids in macular edema 
The rationale for the use of coticosteroids in the treatment of diabetic 
macular edema follows from the observation that the breakdown of the blood 
retinal barrier leads to the edemaxvi and is in part mediated by Vascular endothelial 
growth factor (VEGF). Corticosteroids have been shown to inhibit VEGF and 
other cytokines and growth factors, thereby regulating endothelial cell tight 
junctions. In addition, they inhibit prostaglandin and leukotriene synthesis, which 
results in a local reduction of inflammatory mediators. The resultant anti-
inflammatory effect contributes to the reduction of edema.xvii Increased diffusion 
by modulation of calcium channelsxviii could also account for the efficacy of the 
corticosteroids in reducing macular edema. In the last 5 years, intravitreal steroids – 
and triamcinolone in particular – have gained widespread use as a treatment of all 
forms of ME. Intravitreal triamcinolone (IVTA), alone or in combination with laser 
therapy, has been the subject of multiple investigations of therapy for DME. In 
general, IVTA reduces retinal thickening on OCT and improves vision in a 
substantial number of patients. Patients with a cystoid component to their ME 
respond better. However, the duration of the effect varies and ME recurrence and 
visual decline are often observed 4 to 6 months after injection. Repeated therapy is 
often limited by side effects. Intraocular pressure elevation occurs in about one 
third of patients, which can (rarely) require glaucoma surgery. Acceleration of 
cataract formation, endophthalmitis, and retinal detachment are the other adverse 
events that should be considered and discussed with the patient as part of informed 
consent. IVTA has also been used for treatment of vein occlusion-associated ME. 
It has been employed more extensively for CRVO because laser therapy is not an 
option in this disease. A recently published 1-year study revealed a short-term 
visual benefit in some patients with CRVO-associated ME who were treated with 
IVTA, although their vision generally returned to pretreatment levels at 1 year 
despite repeated injections.xix It has also been observed that the rate of intraocular 
pressure rise and need for glaucoma surgery appears to be higher in this subset of 
patients than in those with DME. The SCORE (Standard Care vs. Corticosteroid 
for Retinal Vein Occlusion) Study, a National Eye Institute-sponsored randomized 
clinical trial of intravitreal steroid for BRVO- and CRVO-associated ME, is 
currently underway and should provide more definitive answers regarding the 
safety and efficacy of treatment with IVTA for cases of vein occlusion-associated 
ME. 
Finally, IVTA has been used in uveitic ME. A retrospective review of 16 
patients with chronic, refractory uveitic CME who received at least 1 injection of 
IVTA had results that mirrored those seen when this medication was used as a 
treatment for ME caused by other diseases.xx At a mean follow-up of 34 weeks, 
there was a sustained improvement in visual acuity in 55% of patients, although 
there was a relapse or persistence of CME in half of all patients receiving this 
treatment. One of the 20 eyes required glaucoma implant surgery for increased 
pressure. There are several alternative intravitreal steroid delivery devices currently 
under investigation for ME. A non biodegradable intravitreal implant containing 
fluocinolone acetonide which isinserted via a pars plana incision, has been 
approved by the FDA for the treatment of severe uveitis. In a clinical trial of 278 
patients with refractory posterior uveitis, vision stabilized or improved in 87% of 
subjects in the treatment group, generally due to reductions in CME, over the 34-
week follow-up period.xxi About half the eyes required topical ocular 
antihypertensive medications and 6% required glaucoma surgery. This implant is 
currently undergoing clinical trials for diabetic and uveitic ME. Preliminary results 
from a DME study of 197 patients showed a significantly better rate of 3-line 
improvement in vision and resolution of ME at 2 years for patients who received 
the implants.xxii This advantage was lost by 3 years presumably because the effect 
of the implant, which provides about 30 months of constant release, had dissipated. 
However, about 30% of implant recipients developed sustained elevation of 
intraocular pressure that ultimately required glaucoma surgery and 95% of phakic 
patients required cataract extraction. 
 
Intravitreal anti-VEGF compounds:  
Anti-VEGF agents work to restore the normal permeability of the blood-retinal 
barrier. Pegaptanib sodium an anti-VEGF pegylated aptamer, has been studied in a 
Phase II randomized, double-blind, controlled trial of DME in 172 subjects.xxiii 
Patients received at least 3 injections at 6-week intervals and were followed for 36 
weeks. The patients assigned to pegaptanib were more likely to gain at least 10 
letters (34% vs. 10%, p = 0.003), were more likely to show a reduction in central 
retinal thickness (42% vs., 16%, p=0.02) and, at follow-up examinations, were 
deemed less likely to need additional photocoagulation therapy (25% vs. 48%, p = 
0.04). Ranibizumab (Lucentis®), another intravitreal anti-VEGF agent that has 
been FDA-approved for treatment of wet age-related macular degeneration, was 
studied in a small series of 10 patients with DME and found to significantly reduce 
foveal thickness and improve vision.xxiv Larger, randomized trials are necessary to 
assess the significance of this preliminary finding. Bevacizumab is a recombinant, 
humanized, monoclonal antibody directed against VEGF. Avastin has received 
FDA approval as an intravenous drug for treatment of metastatic colon cancer. An 
intravitreal formulation was first used off-label for the treatment of age-related 
macular degeneration. Subsequently, there have been a number of case series 
examining bevacizumab for the treatment of ME. In cases of diffuse DME that 
failed other treatments, intravitreal injection of bevacizumab was associated with 
improved vision and decreased retinal thickness 12 weeks after the first 
injection.xxv Most of the patients received >1 bevacizumab injection during follow-
up. A recent study of intravitreal bevacizumab treatment for ME in patients with 
CRVO revealed a significant decrease in mean central retinal thickness (887 to 372 
μm, p < 0.001), and improved visual acuity (defined as halving the visual angle) in 
14 of 16 eyes.xxvi Patients had received an average of 2.8 injections and were 
followed for a mean of 3 months. No adverse outcomes occurred. These 
encouraging short-term results need to be validated in prospective studies. 
Bevacizumab has been tried in patients with ME secondary to uveitis. In one case 
series, in which patients were followed for at least 2 months after a single 
intravitreal injection, about 70% of treated patients had a decrease in foveal 
thickness, but only 40% had improved visual acuity by ≥2 lines.xxvii All patients 
had failed other treatments for their ME, though their inflammation was quiescent. 
Thus, for patients with difficult-to-control ME, bevacizumab may be a therapeutic 
option with reasonably good outcomes. 
ESTABLISHED AND EXPERIMENTAL TREATMENTS FOR 
MACULAR EDEMA OF DIFFERENT ETIOLOGIES. 
Diabetic macular 
edema 
Treatments with established efficacy by large RCTs
Grid or focal laser photocoagulation 
Treatments with potential efficacy,limited or no 
RCT data 
Periocular triamcinolone, intravitreal 
triamcinolone, intravitreal pegaptanib sodium, 
intravitreal ranibizumab, intravitreal bevacizumab,  
CRVO Treatments with established efficacy by large RCTs 
– None 
Treatments with potential efficacy, but limited or 
no RCT data 
Perioculartriamcinolone, intravitreal triamcinolone, 
intravitreal bevacizumab, intravitreal ranibizumab, 
vitrectomy with or without radial optic neurotomy 
Post operative 
CME 
Treatments with established efficacy 
Topical steroids and NSAIDs; vitrectomy if 
vitreous wick to surgical wound 
Treatments with potential efficacy,but limited or no 
RCT data 
Perioculartriamcinolone, intravitrealtriamcinolone 
 
AIM OF THE STUDY 
I. To study the  visual acuity response of intravitreal triamcinolone in cases of: 
1. Diffuse DME not responding to laser therapy. 
2. CME after intraocular surgeries not responding to topical anti inflammatory 
drugs 
3. CME after retinal venous occlusion. 
 
II. To evaluate the change in macular thickness by OCT following injection in 
above said conditions. 
III. To evaluate the safety and efficacy of intravitreal injection of Triamcinolone   
 
 
 
 
INCLUSION CRITERIA 
1. Refractory diffuse DME unresponsive to focal laser photocoagulation 
2. CME after intraocular surgeries not responding to topical anti inflammatory 
drugs 
3. CME after retinal venous occlusion. 
4. Central subfield macular thickness greater than 200 µm 
 
EXCLUSION CRITERIA 
1. History of glaucoma or ocular hypertension 
2. Loss of vision as a result of other causes 
3. Systemic corticosteroid therapy 
4. Severe systemic disease 
5. Any condition affecting follow-up or documentation 
6. Uncontrolled diabetes, uncontrolled hypertension. 
7. History or evidence of ongoing uveitis.  
 
 MATERIALS AND METHODS 
This study was carried out in the department of vitreo-retina services of 
RIOGOH, Chennai from May to November 2009. Patients who were referred to 
Retina clinic with provisional diagnosis of DME, post op CME, BRVO and CRVO 
were screened and selected for the study. 
         All the patients were taken a brief history, and subjected to detailed systemic 
and ophthalmic evaluation. 
         Anterior segment examination with Slit lamp biomicroscope and posterior 
segment examination using 90D, binocular indirect ophthalmoscope and a detailed 
fundus drawings were done and Fundus photograph was also taken for 
documentation. Fundus fluorescein angiography and Optical coherence 
tomography were done for all the patients. 
A commercially available Triamcinolone (4mg/0.1ml)  was prepared for 
each patient and placed in a tuberculin syringe  using aseptic techniques. After the 
eye had been prepared in a standard fashion using 5% povidone iodine and topical 
antibiotics, 4 mg (0.1 ml) Triamcinolone  was injected intravitreally via the pars 
plana. After the injection, intraocular pressure and retinal artery perfusion were 
checked, and patients were instructed to administer topical antibiotics for 3 days. 
Patients were called 2 to 3 days after injection and were re examined within 1 
week. 
Intravitreal injections–procedure guidelines: 
            Injection procedure guidelines include consideration of pre existing 
conditions such as active external infection, eyelid abnormalities, povidone iodine, 
lid scrubs, pre injection topical antibiotics, lid speculum, drape, gloves, and 
anaesthesia and post injection topical antibiotics.  
           In general the risk of endophthalmitis following intra vitreal injection is 
estimated to be approximately < 0.1%.  
Guidelines for intra vitreal injection: 
1. Povidone iodine for ocular surface, eyelid and eye lashes 
2. Use of speculum and avoid contamination of the needle with eye lid margin 
3. Avoid extensive massage of the eye lids either pre or post injection 
4. Dilate pupil 
5. Adequate use of anaesthetic (topical drops/ sub conjunctival injection) 
6. Avoid prophylactic or post injection paracentesis 
7. IOP to be checked following injection 
8. Dilated fundoscopic examination should be performed following injection to 
confirm central retinal artery perfusion and intra ocular location of the drug. 
Guidelines for follow up: 
Patients were followed up on the immediate day following intra vitreal 
injection. They were followed up every week for 1 month, then every 2 weeks 
subsequently. The results published are for a period extending to six months of 
followup. However patients were instructed to contact ophthalmologist if there if 
increased ocular redness or discomfort or decreased vision compared to that 
present right after the injection procedure. 
Main outcome measures: 
• Best corrected visual acuity (Snellen’s chart) 
• Macular thickness by OCT  
• Intraocular pressure by Goldmann’s applanation tonometry. 
OBSERVATIONS AND RESULTS 
Age distribution. 
Total no. of patients- 32 
Table - 1 
Age distribution No of patients Percentage 
20-40 yrs 2 6 
40-60 yrs 14 44 
60-80 yrs 16 50 
 
           
Most of  the patients in our study were in the age group of 60-80 yrs(50%). 
The oldest patient was 74 years of age while the youngest was 25 years. 
 
Sex distribution 
Table - 2 
Sex No of patients percentage 
Male 13 41 
Female 19 59 
 
             
 
 
 
 Indications for treatment 
Table - 3: 
Indications No of patients Percentage(%) 
Diabetic macular edema 18 56 
Post Op CME 9 28 
Retinal vein occlusion with CME 5 16 
 
 
Out of the many causes for macular edema three of the most common causes 
were included in this study , namely diabetic macular edema (56 % patients) , post 
surgery macular edema( 28% patients) and post retinal venous occlusion macular 
edema ( 16 % patients). 
Results of intravitreal triamcinolone in diabetic CME 
Pre treatment visual acuity 
Table - 4 
 
Visual acuity No.of patients Percentage 
2/60 – 4/60 3 17 
4/60 – 6/60 4 22 
6/60 – 6/24 11 61 
 
Post treatment visual acuity 
Table - 5 
Visual acuity No.of patients Percentage 
2/60 – 4/60 1 6 
4/60 – 6/60 3 17 
6/60 – 6/24 8 33 
>6/24 6 44 
 
Comparison between Pre and Post treatment Visual acuity in DME 
 
There was a distinct improvement in visual acuity post injection. The pre 
treatment VA ranged from 2/60 to 6/24 ( least being 6/24). After treatment the VA 
for 6 patients (44%) improved to >6/24.  
Pre treatment macular thickness 
Table - 6 
Macular thickness No.of cases Percentage 
200-400µ 9 50 
400-600µ 4 22 
600-800µ 3 17 
800-1000µ -- - 
More than 1000µ 2 11 
 
Post treatment macular thickness 
Table - 7 
Macular thickness No.of cases Percentage 
<200 1 5 
200-400µ 16 89 
400-600µ 1 6 
>600µ 0 0 
 
Comparison between pre treatment and post treatment macular thickness 
 
The patients had a pre treatment macular thickness that ranged from 200 to 
1200µ with about 50% having thickness >400µ. After treatment only 1 patient 
(6%) had persistent macular thickness > 400µ. Most of the patients had reduction 
in their macular thickness to levels between 200-400µ with one patient achieving 
thickness <200µ. 
Pre treatment intraocular pressure 
Table - 8 
Intraocular pressure No.of cases Percentage 
10-12mm Hg 3 17 
12-14mm Hg 6 33 
14-16mm Hg 3 17 
16-18mm Hg 6 33 
18 – 20 mm Hg 0 - 
>20 mm Hg 0 - 
 
Post treatment IOP 
Table - 9 
Intraocular pressure No.of cases Percentage 
10-12mm Hg 1 6 
12-14mm Hg 5 28 
14-16mm Hg 4 22 
16-18mm Hg 6 33 
        18 – 20 mm Hg 0 - 
              >20 mm Hg 2                  11 
 
 Comparison of pre and post treatment IOP in DME 
 
Most patients maintained their IOP within the normal range with <2mm 
difference between pre and post treatment IOP. However 2 patients had an IOP of 
22 mm Hg and 24 mm Hg starting at 10 weeks. These patients were treated with 
topical β- blocker (0.5% timolol maleate) and reviewed. They were maintaining 
their IOP at 18 mm Hg at the end of 12 weeks. 
Results of intravitreal Triamcinolone in post op macular edema 
Pre treatment Visual acuity 
Table - 10 
Visual acuity No.of patients Percentage 
2/60 – 4/60 3 33 
4/60 – 6/60 2 22 
6/60 – 6/24 4 45 
 
Post treatment Visual Acuity 
Table - 11 
Visual acuity No.of patients Percentage 
2/60 – 4/60 2 22 
4/60 – 6/60 2 22 
6/60 – 6/24 5 56 
 
Pre and post treatment VA comparison in post Surgical CME 
 
The post treatment visual acuity showed a modest increase with 56% 
patients having a VA of 6/60 to 6/24 compared to 45% in the same range before 
treatment. 
Pre treatment macular thickness 
Table - 12 
Macular thickness No. of cases Percentage 
200-400µ 5 62 
400-600µ 2 25 
600-800µ 0 0 
800-1000µ 1 13 
More than 1000µ 0 0 
 
Post treatment macular thickness 
Table - 13 
Macular thickness No. of cases Percentage 
<200 1 11 
200-400µ 8 89 
400-600µ 0 0 
>600µ 0 0 
 
 
 
Comparison between pre and post treatment macular thickness in post 
surgical macular edema 
 
The macular thickness was between 200 to 1100 µ pre treatment. 62% had 
thickness between 200 to 400µ. 38% had between 400 to 1100µ. Post treatment all 
patients had macular thickness less than 400µ with one patient having reduced 
thickness < 200µ. However this marked reduction in macular thickness did not 
correspond to an equivalent increase in visual acuity. This could be due to the long 
standing macular edema which could lead to photoreceptor loss. 
 Pre treatment IOP 
Table - 14 
Intraocular pressure No. of cases Percentage 
10-12mm Hg 0 0 
12-14mm Hg 2 22 
14-16mm Hg 3 33 
16-18mm Hg 4 45 
        18 – 20 mm Hg 0 - 
              >20 mm Hg 0 - 
 
Post treatment IOP 
Table - 15 
Intraocular pressure No.of cases Percentage 
10-12mm Hg 0 0 
12-14mm Hg 2 22 
14-16mm Hg 2 22 
16-18mm Hg 5 56 
        18 – 20 mm Hg 0 - 
              >20 mm Hg 0 - 
 
 
Comparison between pre and post treatment IOP in post surgical macular 
edema 
 
Most of the patients maintained their IOP at their pre treatment levels except 
for one patient who had his IOP raised by 2mm Hg at 12 weeks. However this was 
within the physiologically accepted normal range. 
 
  
Results of intravitreal Triamcinolone in CME due to retinal venous 
occlusion. 
Pre treatment visual acuity 
Table 16: 
Visual acuity No. of patients Percentage 
2/60 – 4/60 3 60 
4/60 – 6/60 0 0 
6/60 – 6/24 2 40 
 
Post treatment visual acuity 
Table 17: 
Visual acuity No. of patients Percentage 
2/60 – 4/60 2 40 
4/60 – 6/60 1 20 
6/60 – 6/24 2 40 
 
 
 
Comparison Between Pre And Post Treatment Visual Acuity In Retinal 
Venous Occlusion 
 
T
he 
visu
al 
acui
ty 
sho
wed 
a 
marginal improvement with only 1 patient having an improvement by 3 meters ( 
3/60 to 6/60) . Other patients had an improvement by one line on an average. 
Pre treatment macular thickness 
Table - 18 
Macular thickness No. of cases Percentage 
>200 0 0 
200-400µ 3 60 
400-600µ 1 20 
600-800µ 1 20 
800-1000µ 0 0 
More than 1000µ 0 0 
 
Post treatment macular thickness. 
Table - 19 
Macular thickness No. of cases Percentage 
>200 2 20 
200-400µ 3 80 
400-600µ 0 0 
>600µ 0 0 
 
Comparison between pre and post treatment macular thickness in 
retinal venous occlusions 
 
The macular thickness showed a significant improvement. Prior to treatment 
40% patients had thicknesses of > 400µ. After treatment all the patients had 
thickness within 400 µ, with 2 patients having reduction to < 200µ. However, 
again this drastic reduction did not correspond to improved visual acuity most 
likely due to long standing macular edema. 
 
 IOP measurements 
Table 20: 
Intraocular pressure Pre treatment Post treatment 
10-12mm Hg 0 0 
12-14mm Hg 2 2 
14-16mm Hg 3 3 
>16mm Hg 0 0 
All the patients in this group maintained their IOP at their pre treatment 
levels. They were closely followed up and examined for the development of 
anterior segment neovascularisation. No patient was seen to develop this 
complication at 12 weeks. 
 
 
 
 
 DISCUSSION 
The administration of intravitreal triamcinolone is appealing for a number of 
reasons. In a country like India with a significant number of diabetics, visual 
morbidity due to diabetic macular edema is high. As of current practice, laser 
treatment as advocated by the ETDRSxxviii remains the standard therapy of DME. 
However refractory DME can be considered for treatment with pharmacological 
agents like intravitreal Triamcinolone or anti VEGF agents. There have been RCTs 
which have demonstrated that intravitreal triamcinolone  alone can provide visual 
and anatomical benefits for upto 2 years ( Gillies et al, Ophthalmology 2006). Anti 
VEGF agents though a promising mode of therapy , remains a costly affair in a 
developing economy like India. Anti VEGF agents for macular edema await phase 
III clinical trials. In this scenario , therapy with intravitreal corticosteroids can be 
considered for individual  patients after a risk-benefit evaluation  . 
In cases of macular edema due to venous occlusions, the recently concluded 
SCORE( Standard Care vs Corticosteroids for Retinal Vascular occlusions) study 
clearly mentions a benefit of intraocular triamcinolone as compared to standard 
therapy in CRVO ( SCORE-CRVO trial). In cases of macular edema due to BRVO 
triamcinolone and grid lases show a comparable respone, however triamcinolone 
can be used for macular edema not responding to grid laser therapy.xxix 
SUMMARY 
• This is a six month prospective , non randomized clinical study to evaluate the 
efficacy and safety of intravitreal triamcinolone in the treatment of macular 
edema due to causes like diabetes, post surgical and post venous obstruction, 
which was refractory to conventional treatment. 
• The main aim was to evaluate the improvement in visual acuity and decrease in 
macular thickness in the above said conditions after intravitreal injection.  
• The occurrence of adverse effects known to intraocular steroids like increase in 
the intraocular pressure and progression of cataract were also noted. 
• Of the 32 patients who were enrolled for this study 19 were female (59%) and 
13 were male (41%) 
• The indications for treatment were diabetic macular edema (56%), post surgical 
macular edema (28%) and edema secondary to retinal venous occlusions(16%). 
Visual acuity: 
 
• The VA in diabetic maculopathy showed a definite  increase with 44% patients 
showing an increase in VA better than 6/24. There was an increase by 3 lines in 
about 50% of the patients 
• In post surgical macular edema 2 patients showed an improvement of 2 lines. 
56% patients had a VA ranging from 6/60 to 6/24 whereas pre treatment 45% 
patients had VA in the same range. 
• In the treatment of edema secondary to retinal venous occlusion , the visual 
acuity showed an improvement by one line(50%) on an average. 2 patients had 
about 3 lines of improvement. 
• In summary, this study shows that the vast majority of patients demonstrated 
stability or improvement of the VA. Of those few patients with a visual decline, 
the change was felt to be due to disease progression rather than drug toxicity. 
Macular thickness: 
• The reduction in macular thickness in DME after administration of 
triamcinolone was substantial. Pre treatment the macular thickness varied from 
200 to 1200µ. After treatment most of the patients (89%) had a reduction within 
the range of  180 to 300µ.Patients also had a corresponding increase in their 
visual acuity. 
• In post surgery CME, the macular thickness was within the range of 200 to 
1100 µ. The mean baseline macular thickness was 400µ. Post injection all the 
patients had macular thickness less than 400µ with 11 %  having thickness less 
than 180µ.  
• In cases of macular edema secondary to venous occlusion, the results were 
encouraging. Prior to treatment 40% patients had thicknesses of > 400µ. After 
treatment all the patients had  thickness within 400 µ, with 2 patients having 
reduction to < 200µ. However, again this drastic reduction did not correspond 
to improved visual acuity most likely due to long standing macular edema with 
associated photoreceptor loss. 
Intra ocular pressure measurements: 
• The IOP for most patients remained within the normal physiological range. The 
mean IOP noted for all patients was 16±2mm Hg. However 2 patients showed a 
rise in IOP occurring around 10 weeks of followup. These patients were started 
on topical aqueous suppressants (0.5 % timolol maleate) and were seen to be 
maintaining their IOP within the physiological limits on subsequent visits. None 
of the patients with increased IOP needed multiple drugs or trabeculectomy. 
 
Conclusions 
Intravitreal Triamcinolone (4 mg) treatment is well tolerated over 6 
months with significant safety and efficacy.   
Nevertheless, this is a small interventional study, with no comparison arm to 
quantify the actual magnitude of benefit of this treatment modality compared with 
other therapies.  
This would have to be studied subsequently in larger studies and also needs 
to be compared with other VEGF inhibitiors regarding safety and efficacy. 
 
 
 
 
 
 
 
Comparison between  pre and post treatment macular OCT scans 
CASE - 1 
   
       FIGURE 1: Pre injection: OCT shows cystoid spaces intraretinally with serous macular 
detachment. Central macular thickness is 1111µ. 
   
FIGURE  1:  24 weeks post injection: Repeat OCT shows reduction in the cystoids spaces 
with macular thickness now being 183µ 
 
CASE - 2  
   
FIGURE 1: Pre injection: multiple cystoid spaces with macular detachment 
   
FIGURE 2:  24 weeks post injection: 50% reduction in macular thickness. VA also showed 
comparable improvement. 
    
 
 
CASE - 3  
  
 FIGURE 1: Pre injection: cystoid change in the retina noted pre treatment. 
 
 
  
FIGURE 2: 24 weeks post injection, the cystoid edema has completely resolved with 
reduction in macular thickness. However the VA showed a minimal improvement (by1 
line). The patient had defective vision post venous occlusion for about 1 year. 
CASE - 4 
     
FIGURE 1: Pre treatment 
   
FIGURE 2: 24 weeks post treatment 
 
 
 
 
Case 5 
 
FIGURE 1: Pre treatment 
  
FIGURE 2: Post treatment reduction in macular edema 
  
 
 
 
                                                                                                                                                                                               
PROFORMA 
 
Case-Information: 
Name    : 
Age    : 
Sex     : 
Occupation   : 
OP No.   : 
Address   : 
Phone No.    : 
 
Chief complaints  
• Defective vision 
• Distorted vision 
• Pain in the eye 
Past history: 
• Diabetes  -  no of years 
               - type I / II 
 -  On oral hypoglycemics / Insulin 
     -  Whether blood sugar under control 
-  associated with NVG 
-  PRP given / not 
                    If given – no of sittings 
• Hypertension - No of years 
                     - On what medication 
                                                                                                                                                                                               
                        - Associated with ischemic heart disease/hyper lipidemia / 
cerebrovascular insult 
• Ocular surgery - date of surgery 
                         - time since defective vision 
                         -type and duration of topical medications used 
On systemic examination: 
            PR:                                                         BP: 
           RBS:                                         Urine – alb & sugar: 
On ocular examination: 
                                                 RE                                     LE 
Visual acuity           -- 
Tension (By NCT)  -- 
Conjunctiva             -- 
Cornea                     -- 
Iris                           --                 
Ant.chamber            -- 
Lens                         -- 
Slit lamp Ex            -- 
Fields                      -- 
Colour vision           -- 
Fundus by 90D        
Fundus by IDO 
 
Fundus flourescein angiography : Type of leak 
Optical coherence tomography :  Macular thickness 
Diagnosis: 
Treatment history: 
                                                                                                                                                                                               
Under aseptic conditions, under topical anaesthesia, inj. Triamcinolone 
acetonide 4mg is injected intravitreally. 
No.of sittings          -             Date 
Outcome of treatment: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                               
 
KEY TO MASTER CHART 
 
OCT   - Optical coherence tomography 
NPDR  - Non proliferative Diabetic Retinopathy 
CSME  - Clinically Significant Macular Edema 
BRVO  -  Branch Retinal Vein Occlusion 
CRVO  - Central retinal Vein Occlusion 
V/A   - Visual acuity  
PH   - Pinhole 
NIP   - Not Improving with pinhole 
IOP   - Intraocular pressure 
IT/ST   - Inferotemporal / Superotemporal 
 
 
 
                                                                                                                                                                                               
LIST OF SURGERIES PERFORMED 
S. 
No. 
Name Age Sex IP no. Diagnosis Surgeries 
1. Kanniammal 60 F 684392 BE IMC LE ECCE with PCIOL 
2. Maragatham 65 F 785391 RE IMC/LE MC LE ECCE with PCIOL 
3. Elangovan 76 M 790160 RE IMC/LE MC LE ECCE with PI 
4. Perumal 70 M 690437 RE IMC/LE MC LE ECCE with PCIOL 
5. Jayagopal 50 M 692899 BE IMC RE ECCE with PCIOL 
6. Subramani 57 M 793525 RE IMC/LE MC LE ECCE with PCIOL 
7. Kaliammal 68 F 783728 BE Nuclear Cat. RE ECCE with PCIOL 
8. Annammal 60 F 674267 BE MC LE ECCE with PCIOL 
9. Krishnaveni 50 F 725015 BE IMC LE SICS  with PCIOL 
10. Muniyammal 65 F 816095 BE IMC LE SICS with PCIOL 
11. Dhanalakshmi 46 F 785885 BE IMC RE SICS with PCIOL 
12. Ramasamy 65 M 826095 BE IMC RE SICS with PCIOL 
13. Vasantha 38 F 656005 RE PSEUDO/ LE 
IMC 
LE ECCE with PCIOL 
14. Gopal 65 M 776441 BE IMC LE SICS with PCIOL 
15. Chandra 65 F 886336 RE MC/ LE PSEUDO RE SICS with PCIOL 
16. Vellaiyan 55 M 847637 BE MC LE ECCE with PCIOL 
17. Dasappan 35 M 87720 LE EXP. KERATITIS LE MEDIAL  
TARSORRAPHY 
18. Etiappan 58 M 891721 LE-IMC LE – SICS with PCIOL 
19. Mariappan 52 M 792726 LE-IMC LE – SICS with PCIOL 
20. Shanthi 48 F 811986 BE IMC RE SICS with PCIOL 
21. Varadhan 46 M 820826 RE  CDC RE DCR 
22. Sumathy 54 F 762091 LE CDC LE DCT 
23. Baskar 52 M 83940 RE-Matur Cataract  RE – SICS with PCIOL 
24 Venkatesh 56 M 78542 LE-IMC LE – SICS 
25. Lakshmi 72 F 84286 RE CDC RE -  DCT 
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 IOP
4 WEEK                                       8 WEEKS                               16 WKS
VA IOP OCT VA  IOP OCT VA IOP OCT
meena 60 f sev NPDR csme sev NPDR csme 6/24ph6/12 6/60ph 6/36 18 18 218 263 LE IVTA 6/60 P 6/36 18 - 6/24PH6/9 18 220 6/24 ph 6/9 18 210
marimuthu 65 m post op cme ,npdr  mod npdr 6/36nip 6/18 nip 12 14 550 225 RE ivta 6/60 ph 6/36 12 - 6/18ph6/12 12 350 6/12nip 12 259
ramanathan 68 m post  op cme mild npdr 6/36ph6/18 6/36ph 6/9 16 16 329 233 RE ivta 6/36 ph 6/12 14 - 6/24ph 6/9 14 300 6/12ph6/9 14 250
dakshinamoorty 60 m sev. NPDR sev. NPDR 6/60 ph6/24 3/60ph6/60 14 14 1053 1112 Le ivta 5/60ph 6/60 14 - 6/24ph 6/18 16 345 6/12ph6/9 16 195
george prakash 25 m normal post op cme 6/6p 1/60 nip 12 12 620 173 RE ivta 1/60p 14 - 1/60 nip 14 450 3/60nip 16 390
sr.franklin 74 f post op cme normal 6/60 ph6/36 6/18ph6/12 18 18 440 280 RE ivta 6/36 ph 6/18 18 - 6/12ph6/9 18 365 6/9nip 18 315
krisnaveni 55 f sev. NPDR,csme sev. NPDR,csme 1/60 nip 6/36 ph 6/24 18 18 248 236 RE ivta 1/60nip 18 - 1/60 nip 18 380 1/60nip 18 514
sekar 50 m sev NPDR csme sev NPDR 6/60ph6/18 6/12ph6/9 14 14 334 227 RE ivta 6/60PH6/18 14 - 6/18ph6/9 14 290 6/12ph6/9 16 262
usha 60 f IT BRVO mac edem normal 2/60ph3/60 6/12ph6/9 16 16 394 177 RE ivta 3/60 nip 16 3/60nip 18 267 3/60nip 18 167
rani 60 f modNPDR csme modnpdr 6/36ph6/24 6/12ph6/9 12 12 771 190 RE ivta 6/36ph 6/24 12 - 6/24PH6/18 14 554 6/18ph6/12 16 345
padmavathy 55 f normal post op cme 6/36ph6/9 1/60nip 14 14 272 180 RE ivta 2/60nip 14 - 3/60 nip 14 274 4/60 nip 16 260
lalitha 50 f CNVM mac edema armd 1/60nip 6/60nip 18 18 256 137 RE ivta 1/60nip 16 - 2/60nip 16 225 2/60nip 16 225
murugavalli 58 f normal ST BRVOmac edem 6/12ph6/9 6/60nip 16 18 160 288 Le ivta 6/60nip 16 - 6/36nip 18 250 6/24ph6/18 18 200
saroja 60 f sev NPDR csme  sev NPDR Csme 5/60ph6/60 3/60 ph 6/60 14 16 232 996 Le ivta 5/60NIP 22 - 6/60nip 20 180 6/24nip 16 108
govindraj 50 m IT BRVO mac edem sev NPDR csme 6/36ph6/24 1/60ph 3/60 12 12 581 940 Le ivta 2/60nip 14 - 2/60nip 16 478 2/60nip 14 330
bhargavi 64 f modNPDR csme mod npdr csme 6/18ph6/12 6/36nip 16 16 285 370 Le ivta 6/36ph 6/24 16 - 6/36ph6/18 18 240 6/36ph6/18 18 210
gunasundari 70 f sev NPDR csme sev NPDR csme 6/24ph6/18 6/36ph6/24 12 12 200 280 Le ivta 6/36ph18 12 - 6/24ph6/12 16 246 6/12nip 16 220
ranjitham 58 f sev NPDR csme sev NPDR csme 6/60 nip 6/24nip 16 16 396 183 RE ivta 6/60 ph24 16 - 6/60ph6/18 16 320 6/24nip 16 270
muthulaksmi 65 f post op cme normal 6/60nip 6/9ph 6/6 16 18 256 173 RE ivta 6/60ph24 16 - 6/24ph6/18 18 239 6/24ph6/18 18 219
sarojini 67 f post op cme post op cme 6/18 ph 6/12 2/60 nip 16 16 412 996 Le ivta 3/60nip 18 - 6/60nip 18 291 6/36nip 18 181
sundarmurthy 59 m sev NPDR csme mod npdr 5/60 nip 6/24nip 18 18 618 185 RE ivta 6/60nip 18 - 6/60nip 20 516 6/60nip 18 406
gangadaran 57 m post op cme normal 6/60ph6/36 6/18ph6/9 18 18 607 238 RE ivta 6/36ph6/24 18 - 6/24PH6/18 18 450 6/24ph6/12 14 375
gopinath 39 m severe NPDR Csme severe NPDR CSME 3/60nip 4/60nip 18 18 1149 1025 RE ivta 3/60 nip 18 - 6/24ph6/18 16 508 6/18ph6/9 18 235
andal 55 f modNPDR csme mod npdr csme 3/60 nip 6/12p 14 14 394 184 RE ivta 3/60p 16 - 5/60nip 14 270 6/60ph6/24 16 240
ashokamma 53 f modNPDR csme modnpdr csme 6/18nip 6/24nip 14 14 210 250 LE IVTA 6/36nip 14 - 6/24ph6/18 14 220 6/24ph6/12 14 200
kuppamal 60 f ST BRVO sevNPDR CSME 3/60NIP 6/18ph6/12 16 16 322 278 RE ivta 3/60 ph4/60 16 - 6/60 ph 6/36 16 290 6/36ph6/24 16 260
rajendran 62 m ST BRVO gr3 htr 4/60nip 5/60ph6/36 10 10 745 372 RE ivta 3/60 ph 6/60 12 - 4/40 ph 6/60 12 540 5/60ph6/36 16 440
sundarrajan 69 m sev NPDR csme mod NPDR 6/60nip 6/36ph6/12 14 14 665 300 RE ivta 6/60nip 14 - 6/60ph6/24 14 520 6/24ph6/18 14 440
malliga 56 f modNPDR csme mod npdr csme 6/36nip 6/24nip 16 16 462 397 RE ivta 6/24nip 16 - 6/18nip 16 412 6/18ph6/12 16 312
abdulkhader 66 m stBrvo normal 3/60nip 6/36ph6/18 14 14 785 289 RE ivta 3/60nip 14 - 4/60ph5/60 14 512 5/60ph6/60 14 320
janardan 70 m sev NPDR csme sev NPDR csme 6/60nip 6/60nip 18 18 600 690 Le ivta 6/60ph6/36 18 - 6/60ph6/24 18 474 6/18nip 18 320
baby 69 f itBrvo normal 6/60ph6/36 6/24nip 16 16 489 306 RE ivta 6/36nip 16 - 6/36ph6/24 18 320 6/24ph6/18 18 220
POST PROCEDURE   RESULTS                                 
Master Chart
LE
NAME AGE SEX
DIAGNOSIS VA ON PRESENTATION OCT MACULAR THICKNESS PRE INJ      PROCEDURE
RERE LE RE LE RE LE
kumari 58 f post op cme normal 6/60nip 6/12ph6/9 12 12 298 189 RE ivta 6/36ph6/24 12 - 6/36ph6/18 12 220 6/18ph6/12 12 194
